California biotech company Alumis is moving its lupus drug, envudeucitinib, into Phase III trials after mixed results in a mid-stage study. The decision comes despite the drug missing key goals in the Phase IIb LUMUS trial, where it failed to show significant benefits across all patients but performed well in a specific subgroup.
Phase IIb trial falls short but reveals a potential niche
The LUMUS study involved 408 adults with systemic lupus erythematosus (SLE). Participants received one of three doses of envudeucitinib or a placebo over 48 weeks. While the trial aimed to measure the drug’s effect on overall disease activity and steroid use, it did not meet its primary or secondary endpoints in the general population.
Still, the drug produced strong results in patients with high interferon gene signatures. Alumis Chief Medical Officer Dr. Jörn Drappa called the effect “highly compelling.” Studies indicate that roughly half of SLE patients experience persistently high type 1 interferon levels, which are associated with more severe symptoms.
Safety results were consistent, with no unexpected issues reported. The company will now concentrate its Phase III efforts on this patient subset, though it has not excluded broader applications.
Related: ESC 2026 AstraZeneca oral relaxin passes Phase II
Market potential and investor skepticism
If envudeucitinib were to secure approval in SLE, it could become one of the first oral targeted therapies to reach a market GlobalData projects will be worth $5.9 billion across seven major markets by 2034. Alumis CEO Martin Babler believes there could also be a notable opportunity for the drug in conditions like cutaneous lupus erythematosus (CLE) and Sjögren’s disease due to the drug’s positive data in patients with high interferon gene signatures.
Investors responded negatively to the Phase IIb results. Alumis’ stock value plunged 56% after the results debuted, from $21.81 at market close on 31 August to $9.47 at the same time on 1 September.
The company is also preparing a New Drug Application for envudeucitinib in moderate-to-severe plaque psoriasis after the drug secured a Phase III win in January 2026. That submission is expected in the final quarter of 2026.
Regulatory discussions for the SLE Phase III trial will come next. The outcome could decide whether the drug’s focused potential leads to commercial success or if the earlier setback proves too difficult to overcome.
